NASDAQ : MLTX
MoonLake Immunotherapeutics — Financial statements
Healthcare · Biotechnology · Switzerland
Last price 11.78 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.00B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 46.96M | 41.97M | 30.32M | 22.32M | 23.01M | 21.66M |
| Research & Development | 221.38M | 202.86M | 112.77M | 31.80M | 42.05M | 12.64M |
| Operating Expenses | 268.34M | 244.83M | 143.09M | 54.12M | 65.06M | 34.29M |
| Operating Income | -268.34M | -244.83M | -143.09M | -54.12M | -65.06M | -34.29M |
| Interest Expense | -10.09M | -7.25M | ||||
| Currency Exchange Gain (Loss) | 18.00K | 599.00K | 42.00K | 151.00K | 325.32K | -71.59K |
| Other Non Operating Income (Expenses) | 14.26M | 21.77M | 22.09M | 9.99M | 266.42K | -2.63K |
| EBT Excluding Unusual Items | -264.15M | -229.71M | -120.96M | -43.98M | -64.47M | -34.37M |
| Other Unusual Items | -30.00M | |||||
| Pretax Income | -264.15M | -229.71M | -120.96M | -43.98M | -64.47M | -64.37M |
| Income Tax Expense | 1.08M | 611.00K | 282.00K | 94.00K | 36.37K | 5.71K |
| Earnings From Continuing Operations | -265.22M | -230.32M | -121.24M | -44.08M | -64.51M | -64.37M |
| Minority Interest in Earnings | 1.56M | 3.00M | 2.31M | 8.07M | 14.53M | |
| Net Income | -263.67M | -227.32M | -118.94M | -36.01M | -49.97M | -64.37M |
| Net Income to Common | -263.67M | -227.32M | -118.94M | -36.01M | -49.97M | -64.37M |
| Shares Outstanding (Basic) | 69.14M | 64.46M | 62.87M | 49.12M | 29.36M | 7.84M |
| Shares Outstanding (Diluted) | 69.14M | 64.46M | 62.87M | 49.12M | 29.36M | 7.84M |
| EPS (Basic) | -3.81 | -3.53 | -1.89 | -0.73 | -1.70 | -8.21 |
| EPS (Diluted) | -3.81 | -3.53 | -1.89 | -0.73 | -1.70 | -8.21 |
| Free Cash Flow | -225.18M | -196.04M | -117.11M | -43.06M | -55.91M | -42.27M |
| Free Cash Flow Per Share | -3.26 | -3.04 | -1.86 | -0.88 | -1.90 | -5.39 |
| EBITDA | -265.10M | -242.22M | -141.71M | -53.75M | -64.90M | -34.29M |
| D&A For EBITDA | 3.24M | 2.62M | 1.39M | 370.00K | 164.78K | 5.96K |
| EBIT | -268.34M | -244.83M | -143.09M | -54.12M | -65.06M | -34.29M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 477.90M | 334.52M | 180.43M | 451.17M | 39.51M | 8.04M |
| Short-Term Investments | 59.12M | 59.45M | 267.60M | 59.84M | 32.61M | |
| Cash & Short-Term Investments | 537.03M | 393.97M | 448.03M | 511.01M | 72.11M | 8.04M |
| Other Receivables | 6.56M | 4.87M | 2.84M | 1.06M | 217.13K | 148.77K |
| Receivables | 6.56M | 4.87M | 2.84M | 1.06M | 217.13K | 148.77K |
| Prepaid Expenses | 26.45M | 22.86M | 23.42M | 2.10M | 4.18M | 1.45M |
| Total Current Assets | 570.04M | 421.69M | 474.29M | 514.17M | 76.51M | 9.64M |
| Property, Plant & Equipment | 2.56M | 2.14M | 3.64M | 3.95M | 331.97K | 45.74K |
| Long-Term Deferred Charges | 1.34M | 596.00K | ||||
| Other Long-Term Assets | 8.42M | |||||
| Total Assets | 573.95M | 424.43M | 477.93M | 526.54M | 76.84M | 9.68M |
| Accounts Payable | 17.04M | 365.00K | 182.00K | 325.68K | 157.31K | 30.90K |
| Accrued Expenses | 24.76M | 42.78M | 20.27M | 8.07M | 7.24M | 4.76M |
| Short-Term Debt | 15.00M | |||||
| Current Portion of Leases | 1.25M | 1.23M | 1.37M | 1.20M | 153.63K | |
| Current Income Taxes Payable | 2.35M | 1.09M | 642.00K | 367.98K | 109.83K | 63.92K |
| Other Current Liabilities | 1.23M | |||||
| Total Current Liabilities | 45.39M | 45.48M | 22.46M | 9.97M | 7.67M | 21.09M |
| Long-Term Debt | 99.51M | 74.10M | ||||
| Long-Term Leases | 772.00K | 374.00K | 1.46M | 2.50M | 128.95K | |
| Pension & Post-Retirement Benefits | 74.00K | 621.00K | 583.43K | 282.21K | 239.86K | |
| Total Liabilities | 145.75M | 119.95M | 24.54M | 13.05M | 8.08M | 21.33M |
| Common Stock | 8.00K | 7.00K | 6.00K | 6.30K | 5.27K | 38.54K |
| Additional Paid-In Capital | 1.02B | 766.78M | 677.41M | 609.97M | 129.19M | 42.06M |
| Retained Earnings | -594.42M | -462.91M | -235.59M | -116.66M | -80.65M | -53.64M |
| Treasury Stock | -6.20K | |||||
| Comprehensive Income & Other | 630.00K | 604.00K | 5.00M | 2.36M | 350.95K | -168.18K |
| Total Common Equity | 428.19M | 304.48M | 446.82M | 495.68M | 48.90M | -11.72M |
| Minority Interest | 6.57M | 17.82M | 19.87M | |||
| Shareholders' Equity | 428.19M | 304.48M | 453.39M | 513.49M | 68.77M | -11.65M |
| Total Liabilities & Equity | 573.95M | 424.43M | 477.93M | 526.54M | 76.84M | 9.68M |
| Total Debt | 101.53M | 75.71M | 2.83M | 3.70M | 282.58K | 15.00M |
| Net Cash (Debt) | 435.50M | 318.26M | 445.20M | 507.31M | 71.83M | -6.96M |
| Net Cash Per Share | 6.30 | 4.94 | 7.08 | 10.33 | 2.45 | -0.89 |
| Filing Date Shares Outstanding | 85.11M | 71.73M | 63.28M | 62.87M | 39.15M | 303.77K |
| Total Common Shares Outstanding | 83.61M | 71.37M | 63.08M | 60.47M | 38.98M | 303.77K |
| Working Capital | 524.65M | 376.22M | 451.83M | 504.20M | 68.85M | -11.45M |
| Book Value Per Share | 5.12 | 4.27 | 7.08 | 8.20 | 1.25 | -38.57 |
| Tangible Book Value | 428.19M | 304.48M | 446.82M | 495.68M | 48.90M | -11.72M |
| Tangible Book Value Per Share | 5.12 | 4.27 | 7.08 | 8.20 | 1.25 | -38.57 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -263.67M | -227.32M | -118.94M | -36.01M | -49.97M | -64.37M |
| Depreciation & Amortization | 3.24M | 2.62M | 1.39M | 370.00K | 164.78K | 5.96K |
| Asset Writedown & Restructuring Costs | 5.82M | |||||
| Stock-Based Compensation | 23.20M | 12.90M | 7.28M | 7.11M | 9.65M | 10.86M |
| Other Operating Activities | -954.00K | -4.08M | -2.53M | -8.03M | -14.16M | 90.38K |
| Change in Accounts Receivable | -3.15M | -2.02M | -1.79M | -840.00K | -68.36K | -178.53K |
| Change in Accounts Payable | -42.00K | 20.56M | 7.16M | 1.58M | -1.31M | 1.88M |
| Change in Other Net Operating Assets | 16.20M | 1.34M | -9.15M | -6.96M | -197.22K | 3.68M |
| Operating Cash Flow | -225.18M | -196.01M | -116.59M | -42.78M | -55.89M | -42.21M |
| Capital Expenditures | -35.00K | -520.00K | -284.00K | -16.01K | -60.85K | |
| Investment in Securities | 58.91M | 203.03M | -205.08M | -24.90M | -32.32M | |
| Investing Cash Flow | 58.91M | 202.99M | -205.60M | -25.18M | -32.34M | -60.85K |
| Long-Term Debt Issued | 73.02M | |||||
| Total Debt Issued | 24.47M | 73.02M | 18.00M | |||
| Short-Term Debt Repaid | -15.00M | |||||
| Total Debt Repaid | -15.00M | |||||
| Net Debt Issued (Repaid) | 24.47M | 73.02M | -15.00M | 18.00M | ||
| Issuance of Common Stock | 313.67M | 72.97M | 52.78M | 482.45M | 46.73K | 131.88K |
| Repurchase of Common Stock | -7.44K | |||||
| Other Financing Activities | -1.47M | -2.75M | 134.65M | |||
| Financing Cash Flow | 338.14M | 146.00M | 51.31M | 479.70M | 119.69M | 51.92M |
| Foreign Exchange Rate Adjustments | -648.00K | 1.11M | 128.00K | -76.00K | 8.54K | 2.25K |
| Net Cash Flow | 171.22M | 154.09M | -270.74M | 411.66M | 31.47M | 9.65M |
| Free Cash Flow | -225.18M | -196.04M | -117.11M | -43.06M | -55.91M | -42.27M |
| Free Cash Flow Per Share | -3.26 | -3.04 | -1.86 | -0.88 | -1.90 | -5.39 |
| Levered Free Cash Flow | -131.86M | -120.38M | -92.06M | -24.14M | -32.23M | |
| Unlevered Free Cash Flow | -125.55M | -115.85M | -92.06M | -24.14M | -32.23M | |
| Cash Interest Paid | 7.86M | 5.06M | ||||
| Cash Income Tax Paid | 799.00K | 799.00K | 147.00K | 42.00K | 4.31K | |
| Change in Working Capital | 13.00M | 19.88M | -3.78M | -6.22M | -1.58M | 5.38M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 970.22M | 940.70M | 3.41B | 3.62B | 409.26M | |
| Enterprise Value | 534.72M | 638.24M | 2.93B | 3.19B | 353.09M | |
| Last Close Price | 11.78 | 13.18 | 54.15 | 60.39 | 10.50 | 9.89 |
| PB Ratio | 2.30 | 3.09 | 7.53 | 7.05 | 5.95 | |
| P/TBV Ratio | 2.34 | 3.09 | 7.64 | 7.30 | 8.37 | |
| Debt / Equity Ratio | 0.24 | 0.25 | 0.01 | 0.01 | 0.00 | -1.29 |
| Net Debt / Equity Ratio | -1.02 | -1.04 | -0.98 | -0.99 | -1.04 | -0.60 |
| Net Debt / EBITDA Ratio | 1.64 | 1.31 | 3.14 | 9.44 | 1.11 | -0.20 |
| Net Debt / FCF Ratio | 1.93 | 1.62 | 3.80 | 11.78 | 1.28 | -0.17 |
| Quick Ratio | 11.97 | 8.77 | 20.07 | 51.38 | 9.44 | 0.39 |
| Current Ratio | 12.56 | 9.27 | 21.11 | 51.59 | 9.98 | 0.46 |
| Return on Equity (ROE) | -67.47% | -60.78% | -25.08% | -15.14% | -225.86% | |
| Return on Assets (ROA) | -32.44% | -33.92% | -17.81% | -11.21% | -93.99% | |
| Return on Capital Employed (ROCE) | -50.80% | -64.60% | -31.40% | -10.50% | -94.00% | 300.70% |
| Earnings Yield | -33.45% | -24.16% | -3.48% | -1.00% | -12.21% | |
| FCF Yield | -22.46% | -20.84% | -3.43% | -1.19% | -13.66% | |
| Buyback Yield / Dilution | -9.53% | -2.54% | -27.99% | -67.30% | -274.47% |